Drug Profile
GSK 576389A
Alternative Names: FluAS25 adjuvanted influenza vaccine - GSK; FluAS25 adjuvanted inluenza vaccine - GSK; GSK576389A; Seasonal influenza virus vaccine - GSKLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 01 Jan 2011 Discontinued prior to 2011 - Phase-III for Influenza virus infections (prevention in the elderly) in USA, Germany and Norway (IM)
- 01 Jan 2011 Discontinued prior to 2011- Phase-II for Influenza virus infections (prevention in the elderly) in Denmark, Belgium, Netherlands, Estonia, United Kingdom and Sweden (IM)
- 01 Oct 2007 Phase-II clinical trials in Influenza virus infections (prevention in the elderly) in Belgium, United Kingdom, Germany, Netherlands and Sweden (IM)